glp-1 ra drugs list Drug Comparison in Diabetes and Obesity Treatment Overview of GLP-1 Receptor Agonists

Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting

Disclaimer The content of this article is intended for informational and educational purposes only

Given the observed increased risk of colorectal cancer among patients receiving GLP-1 receptor agonists, clinicians should approach long-term prescribing of these agents with careful consideration, particularly in individuals with additional risk factors for colorectal cancer, such as a family history, obesity, inflammatory bowel disease, or long-standing type 2 diabetes

Preserving muscle mass helps boost metabolism as you lose fat

Despite concerns over affordability and side effects, in May, analysts at Morgan Stanley Research predicted the global obesity drug market could peak at $150 in 2035, up from the firms previous forecast of $105 billion